

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trallemark Office. Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vingnia 22313-1450 www.nspto.gov

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 196726US0 09/686,997 10/12/2000 Olivier De Lacharriere 5836 22850 7590 07/02/2003 OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C. **EXAMINER** 1940 DUKE STREET WANG, SHENGJUN ALEXANDRIA, VA 22314 ART UNIT PAPER NUMBER

> 1617 DATE MAILED: 07/02/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

· · · · · · · · · · · · · · · · · · ·	Applicati n N .	Applicant(s)
	09/686,997	DE LACHARRIERE ET AL.
Office Action Summary	Examiner	Art Unit
•	Shengjun Wang	1617
The MAILING DATE f this communication ap		
Period f r Reply		
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status		
1)⊠ Responsive to communication(s) filed on <u>15</u>	April 2003	
<u> </u>	his action is non-final.	
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is		
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.		
Disposition of Claims  AV  Claim(a) 13 13 16 34 37 33 and 36 45 in/ora	nanding in the application	
4)⊠ Claim(s) <u>12,13,16-24,27-33 and 36-45</u> is/are pending in the application.  4a) Of the above claim(s) is/are withdrawn from consideration.		
5) Claim(s) is/are allowed.		
6) Claim(s) is/are allowed.		
7) Claim(s) is/are objected to.		
8) Claim(s) 12,13,16-24,27-33 and 36-45 are subject to restriction and/or election requirement.		
Application Papers		
9) The specification is objected to by the Examiner.		
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.		
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).		
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.		
If approved, corrected drawings are required in reply to this Office action.		
12) The oath or declaration is objected to by the Examiner.		
Priority under 35 U.S.C. §§ 119 and 120		
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).		
a) ☐ All b) ☐ Some * c) ☐ None of:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>		
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).		
<ul> <li>a) ☐ The translation of the foreign language provisional application has been received.</li> <li>15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.</li> </ul>		
Attachment(s)		•
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of	Summary (PTO-413) Paper No(s) Informal Patent Application (PTO-152)
S. Patent and Trademark Office		

Application/Control Number: 09/686,997

Art Unit: 1617

## **DETAILED ACTION**

Receipt of applicants' amendments and remarks submitted April 15, 2003 is acknowledged.

- 1. The terminal disclaimer filed on April 15, 2003 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of 6,486,147 has been reviewed and is accepted. The terminal disclaimer has been recorded.
- 2. The amendments submitted April 15, 2003 further diversifies the claimed subject matters, and makes it necessary for the following restriction and election requirement.

## Election/Restrictions

- 3. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 12, 13, 16-24, 27-33, and 36-45, drawn to a method of treating skin pigmentation marks, classified in class 424, subclass 401, 59; class 514, subclass 171, 169.
  - II. Claims 12, 13, 16-24, 27-33 drawn to a method of depigmentation and/or bleaching of skin wherein the treated skin does not have particular pigmentation marks, classified in class 424, subclass 401, 59; class 514, subclass 171, 169.
- 4. Inventions I and II are unrelated from each other. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different function and different effects. Particularly, group I is directed to treatment of abnormal pigmentation, and group II is directed to treatment of normal skin for lightening the skin color. They differ with respect to the subject and final results.

Application/Control Number: 09/686,997

Art Unit: 1617

They therefore have different issues regarding patentability and enablement and represent patentable distinct subject matter.

5. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

- 6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 7. Claims 12, 13, 16-24, 27-33, and 36-45, generic to a plurality of disclosed patentably distinct species comprising DHEA, its metabolic derivatives and biological precursors.

  Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Application/Control Number: 09/686,997

Art Unit: 1617

8. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Shengjun Wang, Ph.D. whose telephone number is (703) 308-

Page 4

4554. The examiner can normally be reached on Monday-Friday from 8:30 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, can be reached on (703) 305-1877. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Patent Examiner

Shengjun Wang

June, 28 2003